New models to investigate mechanisms of disease genesis from primitive BCR-ABL+ hematopoietic cells

Annals of the New York Academy of Sciences

Volumn 996, Issue , 2003, Pages 1-9

  Eaves, Connie ^a,c   Jiang, Xiaoyan ^a   Eisterer, Wolfgang ^a   Chalandon, Yves ^a   Porada, G ^b   Zanjani, Esmail ^b   Eaves, Allen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF NEVADA   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Autocrine; BCR ABL; Chronic myeloid leukemia; G CSF; IL 3; NOD SCID mice; Xenotransplant models

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 3; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOKINE PRODUCTION; FETUS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HYPOTHESIS; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; SCID MOUSE; SHEEP; STEM CELL;

ANIMALIA; MURINAE; OVIS ARIES; UNIDENTIFIED RETROVIRUS;

EID: 0037792094     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb03226.x     Document Type: Conference Paper

References (46)

1. SAWYERS, C.L. 1999. Chronic myeloid leukemia. N. Engl. J. Med. 340: 1330-1340.
2. SINGER, J.W., P.J. FIALKOW, L. STEINMANN, et al. 1979. Chronic myelocytic leukemia (CML): failure to detect residual normal committed stem cells in vitro. Blood 53: 264-268.
3. DUBE, I.D., C.M. GUPTA, D.K. KALOUSEK, et al. 1984. Cytogenetic studies of early myeloid progenitor compartments in Ph1-positive chronic myeloid leukaemia (CML). I. Persistence of Ph1-negative committed progenitors that are suppressed from differentiating in vivo. Br. J. Haematol. 56: 633-644.
4. RASKIND, W.H. & P.J. FIALKOW. 1987. The use of cell markers in the study of human hematopoietic neoplasia. Adv. Cancer Res. 49: 127-167.
5. 1+ chronic myelogenous leukemia and effects of intensive treatment. Blood 59: 793-808.
6. COULOMBEL, L., D.K. KALOUSEK, C.J. EAVES, et al. 1983. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N. Engl. J. Med. 308: 1493-1498.
7. EAVES, C.J. & A.C. EAVES. 2001. Progenitor cell dynamics. In Chronic Myeloid Leukemia: Biology & Treatment. A.M. Carella, G.Q. Daley, C.J. Eaves, et al., Eds.: 73-100. Martin Dunitz. London.
8. bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830.
9. DRUKER, B.J., M. TALPAZ, D.J. RESTA, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031-1037.
10. KANTARJIAN, H., C. SAWYERS, A. HOCHHAUS, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J Med. 346: 645-652.
11. EAVES C.J. & A.C. EAVES. 1987. Cell culture studies in CML. In Baillìre's Clinical Haematology. K. Hinton, Ed.: 931-961. Baillière Tindall/W.B. Saunders. London.
12. HOLYOAKE, T., X. JIANG, C. EAVES, et al. 1999. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94: 2056-2064.
13. ICHIMARU, M., T. ISHIMARU, M. MIKAMI, et al. 1981. Incidence of leukemia in a fixed cohort of atomic bomb survivors and controls, Hiroshima and Nagasaki October 1950- December 1978: Technical Report RERF TR 13-81. Radiation Effects Research Foundation. Hiroshima.
14. CURTIS, R.E., J.D. BOICE, JR., M. STOVALL, et al. 1994. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J. Natl. Cancer Inst. 86: 1315-1324.
15. WEISS, H.A., S.C. DARBY, T. FEARN, et al. 1995. Leukemia mortality after X-ray treatment for ankylosing spondylitis. Radiat. Res. 142: 1-11.
16. YONG, A.S.M. & J.M. GOLDMAN. 1999. Relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transpl. 23: 827-828.
17. SOCIE, G., R.E. CURTIS & J.P. KLEIN. 2001. Late complications, including late relapse. In Chronic Myeloid Leukaemia: Biology and Treatment. A. Carella, G.Q. Daley, J.M. Goldman & R. Hehlmann, Eds.: 401-417. Martin Dunitz. London.
18. KALOUSEK, D.K., C.J. EAVES & A.C. EAVES. 1984. In-vitro cytogenetic studies of haemopoietic malignancies. Cancer Surv. 3: 439-463.
19. UDOMSAKDI, C., C.J. EAVES, B. SWOLIN, et al. 1992. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc. Natl. Acad. Sci. USA 89: 6192-6196.
20. PETZER, A.L., C.J. EAVES, M.J. BARNETT, et al. 1997. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 90: 64-69.
21. MAGUER-SATTA, V., S. BURL, L. LIU, et al. 1998. BCR-ABL accelerates C2-ceramide-induced apoptosis. Oncogene 16: 237-248.
22. METCALF, D. & M.A.S. MOORE. 1971. Haematopoietic cells. In Frontiers of Biology. A. Neuberger & E.L. Tatum, Eds.: 1-550. North-Holland. Amsterdam.
23. JIANG, X., A. LOPEZ, T. HOLYOAKE, et al. 1999. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 96: 12804-12809.
24. HOLYOAKE, T.L., X. JIANG, M.W. DRUMMOND, et al. 2002. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 16: 549-558.
25. ZINDSTRA, P.W., E. CONNEALLY, A.L. PETZER, et al. 1997. Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc. Natl. Acad. Sci. USA 94: 4698-4703.
26. YONEMURA, Y., H. KU, F. HIRAYAMA, et al. 1996. Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 93: 4040-4044.
27. SAWYERS, C.L., M.L. GISHIZKY, S. QUAN, et al. 1992. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood 79: 2089-2098.
28. 1 leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J. Clin. Invest. 92: 194-202.
29. SIRARD, C., T. LAPIDOT, J. VORMOOR, et al. 1996. Normal and leukemic SCID-repopulating cells (SRC) co-exist in the bone marrow and peripheral blood from CML patients in chronic phase while leukemic SRC are detected in blast crisis. Blood 87: 1539-1548.
30. DAZZI, F., D. CAPELLI, R. HASSERJIAN, et al. 1998. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood 92: 1390-1396.
31. + cells. Blood 91: 630-640.
32. VERSTEGEN, M.M.A., J.J. CORNELISSEN, W. TERPSTRA, et al. 1999. Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice. Leukemia 13: 618-628.
33. WANG, J.C.Y., T. LAPIDOT, J.D. CASHMAN, et al. 1998. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 91: 2406-2414.
34. WANG, J.C.Y., M. DOEDENS & J.E. DICK. 1997. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89: 3919-3924.
35. HOLYOAKE, T.L., F.E. NICOLINI & C.J. EAVES. 1999. Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. Exp. Hematol. 27: 1418-1427.
36. VAN DER LOO, J.C.M., H. HANENBERG, R.J. COOPER, et al. 1998. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells. Blood 92: 2556-2570.
37. 2 microglobulin-null mice. J. Clin. Invest. 107: 199-206.
38. GUENECHEA, G., O.I. GAN, C. DORRELL, et al. 2001. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat. Immunol. 2: 75-82.
39. KERRE, T.C., G. DE SMET, M. DE SMEDT, et al. 2001. Both CD34+38+ and CD34+38-cells home specifically to the bone marrow of NOD/LtSZ scid/scid mice but show different kinetics in expansion. J. Immunol. 167: 3692-3698.
40. HOGAN, C.J., E.J. SHPALL & G. KELLER. 2002. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc. Natl. Acad. Sci. USA 99: 413-418.
41. 2-microglobulin-deficient NOD-scid mice. J. Immunol. 158: 3578-3586.
42. ZANJANI, E.D., A.W. FLAKE, H. RICE, et al. 1994. Long-term repopulating ability of xenogeneic transplanted human fetal liver hematopoietic stem cells in sheep. J. Clin. Invest. 93: 1051-1055.
43. CIVIN, C.I., G. ALMEIDA-PORADA, M.-J. LEE, et al. 1996. Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo. Blood 88: 4102-4109.
44. JIANG, X., E. NG, C. YIP, et al. 2002. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood 100: 3731-3740.
45. BCR-ABL activity in transduced primary human hematopoietic cells controls lineage reprogramming. Blood 99: 3197-3204.
46. LI, S., S. GILLESSEN, M.H. TOMASSON, et al. 2001. Interleukin 3 and granulocytes-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood 97: 1442-1450.